NEW YORK (GenomeWeb) – Biodesix on Monday said that it has received New York State Clinical Laboratory Evaluation Program (CLEP) approval for its GeneStrat lung cancer liquid biopsy test.

GeneStrat is a blood-based test using a droplet digital PCR platform that detects mutations relevant to patient treatment in non-small cell lung cancer. The current version tests for EGFR sensitizing; EGFR resistance (T790M), KRAS, and BRAF mutations; and EML4-ALK, ROS1 and RET fusion variants.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.